Analysis of FOXO1 mutations in diffuse large B-cell lymphoma

Blood. Volume 121, Issue 18: p. 3666-3674, 2 May 2013

10.1182/blood-2013-01-479865

Diffuse large B-cell lymphoma (DLBCL) accounts for 30% to 40% of newly diagnosed lymphomas and has an overall cure rate of approximately 60%. Previously, we observed FOXO1 mutations in non-Hodgkin lymphoma patient samples. To explore the effects of FOXO1 mutations, we assessed FOXO1 status in 279 DLBCL patient samples and 22 DLBCL-derived cell lines.

FOXO1 mutations were found in 8.6% (24/279) of DLBCL cases: 92.3% (24/26) of mutations were in the first exon, 46.2% (12/26) were recurrent mutations affecting the N-terminal region, and another 38.5% (10/26) affected the Forkhead DNA binding domain. Recurrent mutations in the N-terminal region resulted in diminished T24 phosphorylation, loss of interaction with 14-3-3, and nuclear retention. FOXO1 mutation was associated with decreased overall survival in patients treated with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (P = .037), independent of cell of origin (COO) and the revised International Prognostic Index (R-IPI). This association was particularly evident (P = .003) in patients in the low-risk R-IPI categories.

The independent relationship of mutations in FOXO1 to survival, transcending the prognostic influence of the R-IPI and COO, indicates that FOXO1 mutation is a novel prognostic factor that plays an important role in DLBCL pathogenesis.

Supplemental Data

• GDC Manifests
  • Controlled-Access Data Download Manifest (3 Files)
  • Open-Access Data Download Manifest (6 Files)

• Clinical Data
  • CGCI-NHL Clinical Data

• mRNA
  • CGCI-NHL mRNA-Seq Level 3 Data
  • CGCI-NHL mRNA-Seq Level 3 Data (Controlled)
  • CGCI-NHL mRNA-Seq Metadata

• Whole Exome Sequencing
  • CGCI-NHL WXS Level 3 Data (Controlled)
  • CGCI-NHL WXS Metadata

• Whole Genome Sequencing
  • CGCI-NHL WGS Level 3 Data (Controlled)
  • CGCI-NHL WGS Metadata

• Miscellaneous Files
  • CGCI-NHL Sample Matrix

Additional Resources

• Office of Cancer Genomics (link is external)

Instructions for Data Download

Open Access Data

1. Download the appropriate manifest file from the publication page
2. Use the manifest file to download data using the GDC Data Transfer Tool (DTT) or the GDC API
   • GDC DTT ( Download, User's Guide)
   • GDC API ( User’s Guide)

Controlled Access Data

1. Download the appropriate manifest file from the publication page
2. Download a token from the GDC Data Portal
   • GDC Data Portal ( Launch, User’s Guide)
3. Use the manifest file and token to download data using the GDC DTT or the GDC API
   • GDC DTT ( Download, User’s Guide)
   • GDC API ( User’s Guide)

For assistance, please contact the GDC Help Desk: support@nci-gdc.datacommons.io.